Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) Return on Equity (2020 - 2025)

Benitec Biopharma's Return on Equity history spans 6 years, with the latest figure at 0.34% for Q1 2025.

  • For Q1 2025, Return on Equity rose 126.0% year-over-year to 0.34%; the TTM value through Mar 2025 reached 0.34%, up 126.0%, while the annual FY2024 figure was 0.91%, 1149.0% up from the prior year.
  • Return on Equity for Q1 2025 was 0.34% at Benitec Biopharma, up from 0.34% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.34% in Q1 2025 and bottomed at 7.78% in Q2 2023.
  • The 5-year median for Return on Equity is 1.32% (2021), against an average of 1.76%.
  • The largest annual shift saw Return on Equity tumbled -434bps in 2023 before it skyrocketed 704bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 1.32% in 2021, then decreased by -19bps to 1.56% in 2022, then grew by 26bps to 1.15% in 2023, then soared by 70bps to 0.34% in 2024, then grew by 2bps to 0.34% in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Return on Equity are 0.34% (Q1 2025), 0.34% (Q4 2024), and 0.38% (Q3 2024).